DNA Methylation and Non-small Cell Lung Cancer

Youwei ZHANG; Longbang CHEN
August 2010
Chinese Journal of Lung Cancer;Aug2010, Vol. 13 Issue 8, p821
Academic Journal
Genomic DNA methylation is a major form of epigenetic modification. Hypermethylation could affect the binding of transcription factors to DNA and change the structure of chromatin resulting in silence of tumor suppressor genes, which plays an important role in cancer initiation and progression. In recent years, the study of DNA methylation in lung cancer, mostly in non-small cell lung cancer, has made great progress and become a new target for early detection, risk assessment, prognosis and cancer therapy.


Related Articles

  • Promoter Methylation-Mediated Silencing of β-Catenin Enhances Invasiveness of Non-Small Cell Lung Cancer and Predicts Adverse Prognosis. Miao, Yuan; Wang, Liang; Zhang, Xiupeng; Xu, Xiaohan; Jiang, Guiyang; Fan, Chuifeng; Liu, Yang; Lin, Xuyong; Yu, Juanhan; Zhang, Yong; Wang, Enhua // PLoS ONE;Nov2014, Vol. 9 Issue 11, p1 

    β-Catenin plays dual role in adhesion complex formation and the Wnt signaling pathway. Although β-catenin expression appears to be upregulated and Wnt signaling pathway is activated in the majority of cancers, its expression level seems to be lost in non-small cell lung cancer (NSCLC). We...

  • Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. Lin, Steven H.; Jing Wang; Saintigny, Pierre; Chia-Chin Wu; Giri, Uma; Jing Zhang; Toshi Menju; Diao, Lixia; Byers, Lauren; Weinstein, John N.; Coombes, Kevin R.; Girard, Luc; Komaki, Ritsuko; Wistuba, Ignacio I.; Date, Hiroshi; Minna, John D.; Heymach, John V. // BMC Genomics;2014, Vol. 15 Issue 1, p591 

    Background: DNA methylation is associated with aberrant gene expression in cancer, and has been shown to correlate with therapeutic response and disease prognosis in some types of cancer. We sought to investigate the biological significance of DNA methylation in lung cancer. Results: We...

  • The Role of Cancer-Testis Antigens as Predictive and Prognostic Markers in Non-Small Cell Lung Cancer. John, Thomas; Starmans, Maud H. W.; Chen, Yao-Tseng; Russell, Prudence A.; Barnett, Stephen A.; White, Shane C.; Mitchell, Paul L.; Walkiewicz, Marzena; Azad, Arun; Lambin, Philippe; Tsao, Ming-Sound; Deb, Siddhartha; Altorki, Nasser; Wright, Gavin; Knight, Simon; Boutros, Paul C.; Cebon, Jonathan S. // PLoS ONE;Jul2013, Vol. 8 Issue 7, p1 

    Background: Cancer-Testis Antigens (CTAs) are immunogenic proteins that are poor prognostic markers in non-small cell lung cancer (NSCLC). We investigated expression of CTAs in NSCLC and their association with response to chemotherapy, genetic mutations and survival. Methods: We studied 199...

  • Microarray analysis of promoter methylation in lung cancers. Fukasawa, Masayuki; Kimura, Mika; Morita, Sumiyo; Matsubara, Kenichi; Yamanaka, Sumitaka; Endo, Chiaki; Sakurada, Akira; Sato, Masami; Kondo, Takashi; Horii, Akira; Sasaki, Hiroyuki; Hatada, Izuho // Journal of Human Genetics;Apr2006, Vol. 51 Issue 4, p368 

    Aberrant DNA methylation is an important event in carcinogenesis. Of the various regions of a gene that can be methylated in cancers, the promoter is the most important for the regulation of gene expression. Here, we describe a microarray analysis of DNA methylation in the promoter regions of...

  • Liquid biopsy: A new tool in the management of NSCLC. BOLTZ, KATHY // Oncology Nurse Advisor;May/Jun2015, Vol. 6 Issue 3, p26 

    No abstract available.

  • Bronchial lavage P16INK4A gene promoter methylation and lung cancer diagnosis: A meta-analysis. Yifan, D.; Qun, L.; Yingshuang, H.; Xulin, L.; Jianjun, W.; Qian, M.; Yu Yuman; Zhaoyang, R. // Indian Journal of Cancer;2015 Special Issue 2, Vol. 52, pe96 

    OBJECTIVE: To evaluate the diagnostic value of bronchial lavage P16INK4A promoter methylation and lung cancer. MATERIALS AND METHODS: The databases of PubMed, Medline, China National Knowledge Infrastructure, and Wanfang were electronically searched by two reviewers to find the suitable studies...

  • Aberrant DNA Methylation of OLIG1, a Novel Prognostic Factor in Non-Small Cell Lung Cancer. Brena, Romulo M.; Morrison, Carl; Liyanarachchi, Sandya; Jarjoura, David; Davuluri, Ramana V.; Otterson, Gregory A.; Reisman, David; Glaros, Selina; Rush, Laura J.; Plass, Christoph // PLoS Medicine;Mar2007, Vol. 4 Issue 3, p0572 

    Background Lung cancer is the leading cause of cancer-related death worldwide. Currently, tumor, node, metastasis (TNM) staging provides the most accurate prognostic parameter for patients with non-small cell lung cancer (NSCLC). However, the overall survival of patients with resectable tumors...

  • Using molecular markers as a means of predicting prognosis and outcomes in the treatment of lung cancer. Cosgrove, Jenny // Thorax;Jun2007, Vol. 62 Issue 6, p535 

    The article discusses a study which evaluated the association between the expression of two specific proteins and treatment outcomes of patients with early non-small-cell lung cancer. The increased expression of the gene regulatory subunit of ribonucleotide reductase can reduce metastases,...

  • Expression of WASF3 in patients with non-small cell lung cancer: Correlation with clinicopathological features and prognosis. JIE WU; GUANG-CHUAN WANG; XUE-JUN CHEN; ZHAN-RUI XUE // Oncology Letters;2014, Vol. 8 Issue 3, p1169 

    Wiskott-Aldrich syndrome protein family member 3 (WASF3) is required for invasion and metastasis in different cancer cell types, and has been demonstrated to possess prognostic value in various types of human cancer. However, to the best of our knowledge, the expression profile of WASF3 and its...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics